The Cutera Trusculpt Device For Thigh Circumference Reduction

Cutera Inc.3 sites in 1 country44 target enrollmentAugust 2012

ConditionsBody Fat

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Body Fat
Sponsor: Cutera Inc.
Enrollment: 44
Locations: 3
Primary Endpoint: Change of Thigh Circumference From Baseline
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The objective of this study is to evaluate the safety and efficacy of the Trusculpt (Radio Frequency) device in the reduction of thigh circumference.

Detailed Description

The primary efficacy variable for this study is the comparison of mean change in thigh circumference from baseline to 12 weeks between two arms. The primary research hypothesis is that the mean change in thigh circumference is ≥ 1 cm (indicating mean reduction).

Registry

clinicaltrials.gov

Start Date

August 2012

End Date

June 2013

Last Updated

3 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Female

Investigators

Sponsor

Cutera Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Minimum age of 18 years
•Non-smoking for at least 3 months and willing to refrain from smoking for the duration of the study.
•Post-menopausal, or on birth control and/or no plans to become pregnant for the duration of the study.
•Body Mass Index (BMI) ≤ 30
•Visible fat in the thigh / saddlebag area to be treated
•Subject must be able to read, understand and sign the Consent Form
•Subject must adhere to the follow-up schedule and study instructions
•Subject must adhere to the same diet and/or exercise routine throughout the study, and agree to maintain the same weight throughout the study (within 6 lbs of the weight measure at the baseline assessment)

Exclusion Criteria

•Taking weight-loss medications/supplements
•Simultaneous participation in any other clinical study
•Prior surgical treatment to the target area, e.g., liposuction or abdominoplasty
•Prior treatment to the target area within the last 12 months e.g., radio frequency or cryolysis
•Arteriosclerosis or weakened blood vessels
•Heart disease
•Thromboembolic disease
•Diagnosed or documented immune system disorders (including Panniculitis)
•Bleeding disorders
•Presence of uncontrolled hypertension